Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock

In an unusual move, investors in Edwards Lifesciences (EW) have been placing out-of-the-money (OTM) put options at a significantly higher volume than usual, indicating their bullish outlook on the stock over the next three months. EW, which specializes in heart valve replacement products, is currently trading below analysts' price targets and has shown a slight increase of $90.78 in midday trading.

The stock has rebounded notably since reaching its lowest point following its Q2 earnings release on July 23, when it hit a low of $82.63. Despite solid performance, Nvidia stock may be stuck in a range, while Micron Technology stock appears to be a contrarian opportunity.

Edwards Lifesciences recently reported impressive Q2 results, exceeding analysts' expectations with a 13.6% year-over-year revenue increase. The company also delivered an adjusted earnings per share (EPS) of 78 cents, a 16.4% improvement from the previous year's 67 cents. Furthermore, Edwards Lifesciences raised its revenue guidance and reaffirmed its 2026 EPS guidance, projecting a range of $2.95 to $3.05, up 17.2% from the previous year's EPS of $2.56.

Analysts are now predicting a 2027 EPS of $3.38, equating to a next 12-month (NTM) earnings per share of $3.19, a 6.33% increase.

This surge in OTM put options can be viewed as a sign of investor confidence in Edwards Lifesciences. With the stock currently trading 15.6% below its average forward price/earnings ratio, the unusual volume of these put contracts suggests that investors are likely optimistic about the company's future prospects. Additionally, the high premium of 90 cents for the $77.50 put strike price further supports the bullish sentiment.

By shorting these OTM puts, investors can potentially lower their average cost while still generating income on their existing holdings. These investors may believe that EW stock could be undervalued and are waiting for a more opportune time to buy in. Given the company's strong financial performance and optimistic earnings forecasts, investors who are shorting these put options are confident in Edwards Lifesciences' potential upside.